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Long non-coding RNAs (lncRNAs) are pervasively transcribed in the 
human genome and are known to be functioning in various cellular processes; 
however, the exact mechanisms involved are not well understood. The MYC 
proto-oncogene encodes a transcription factor that regulates cellular functions 
through the activation of its many RNA targets. In this thesis, I address the role of 
MYC-regulated lncRNAs in cancer. 
I first utilized experimental methods, such as microarray, RNA-seq, and 
TCGA analysis, to globally explore the regulatory role of MYC on lncRNAs. One 
lncRNA, DANCR, was identified as one of the most highly MYC-induced targets 
in human cancers. To further confirm that DANCR is directly regulated by MYC, I 
demonstrated by CHIP and CHIP-seq that MYC could bind directly to an E-box 
motif (CACGTG) in the DANCR promoter sequence. Using existing data and my 
own experimental analysis, DANCR expression was shown to be upregulated in 
most primary cancers. I next sought to determine whether DANCR is required for 
MYC-mediated cellular functions in cancer. Abrogation of DANCR expression 
using siRNA resulted in defective cell proliferation. Cell cycle analysis showed 
that the defect triggered by DANCR depletion was a consequence of G1 to S 
phase transition arrest. To assess the expression of genes responsible for this 
phenotype, I examined the expression profiles of cancer cells treated with 
DANCR siRNA. Gene Set Enrichment Analysis (GSEA) showed that a large 
subset of upregulated genes are common to DANCR- and EZH2-depletion. 
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Moreover, p21, an important G1 phase cell cycle regulator, was found to be 
among those genes. I later showed that p21 could be suppressed by both 
DANCR and EZH2. More importantly, a double knock-down experiment of 
DANCR and p21 resulted in the partial rescue of the proliferation reduction 
caused by DANCR knock-down alone, providing evidence that p21 is one of the 
most important targets of DANCR. 
I proposed that MYC induces DANCR, which suppresses p21 via the 
EZH2 pathway, and then provided evidence for this model in a series of IP 
(immunoprecipitation) experiments to establish interactions between pathway 
components. A 3ʹ-domain of DANCR was shown to bind EZH2, whereas a 5ʹ-
domain of DANCR recognized p21 nascent mRNA via RNA–RNA interactions, 
which guides DANCR–EZH2 complexes to the p21 locus. Finally, using 
computational approaches, I also attempted to explore whether my proposed 
mechanism could be generalized to other DANCR targets, and 8 out of 16 genes 
tested seemed to conform to this model. My findings elucidate an important 
missing ‘link’ in the MYC regulated gene network, showing active roles for 
lncRNAs in MYC-mediated cancer, which could be important targets for cancer 
diagnosis and therapy. 
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The MYC proto-oncogene was first discovered in studies of avian tumors 
caused by retroviruses. It was identified as a mammalian homolog of the v-myc 
oncogene of avian myelocytomatosis virus strain 29 (Duesberg and Vogt, 1979; 
Hu et al., 1979; Sheiness and Bishop, 1979; Vennstrom et al., 1982). The MYC 
family includes L-MYC, N-MYC, and B-MYC (Brodeur et al., 1984; Kohl et al., 
1984; Maris, 2010; Nau et al., 1985). MYC expression is tightly regulated by 
several mechanisms (Brooks and Hurley, 2010; Hurley et al., 2006; Levens, 
2010). Dysregulation of MYC is often thought to be one of the most common 
oncogenic factors in cancer (Cole and McMahon, 1999). Through its actions on 
various direct and indirect target genes, the MYC target gene network is involved 
in essentially all cellular processes (Dang, 1999; Grandori and Eisenman, 1997; 
Oster et al., 2002; Secombe et al., 2004). Despite the growing number of studies 
revealing more details of its functions, certain mechanisms whereby MYC 
regulates its downstream targets are not yet fully understood. MYC has been 
shown to stimulate transcription from all three nuclear RNA polymerases (I, II, 
and III), and it was previously shown to regulate the expression of mRNAs, 
rRNAs, tRNAs, and microRNAs. This thesis presents a new mechanism of MYC 
regulation, whereby MYC regulation of gene expression can occur through long 





Oncogenesis and MYC 
MYC is one of the most important oncogenic transcription factors that is 
frequently dysregulated in many human and animal cancers (Cole and McMahon, 
1999; Dang, 1999; Nesbit et al., 1999). Increased MYC expression is often found 
in aggressive cancers (Liao and Dickson, 2000). Translocations between MYC 
on chromosome 8 and immunoglobulin enhancers on chromosomes 2, 14, and 
22 are the causes of Burkitt’s lymphoma, resulting in constitutive MYC 
expression and uncontrolled cellular proliferation (Dalla-Favera et al., 1982; Taub 
et al., 1982). Elevated amplification of MYC expression levels is also a feature of 
many human cancers (Augenlicht et al., 1997; Beroukhim et al., 2010). Several 
studies of transgenic mice established that abnormally expressed MYC in 
different tissues can occur either alone or in combination with additional 
mutations that lead to tumorigenesis (Adams et al., 1985; Beer et al., 2004; 
Chesi et al., 2008; Leder et al., 1986; Pelengaris et al., 1999; Secombe et al., 
2004). In mouse models, universal promotion of cellular proliferation and, in 
some instances, reduction of apoptosis appeared to be the main modes of MYC 
promotion of tumorigenesis (Cappellen et al., 2007; Koh et al., 2011; Wang et al., 
2008a). MYC has also been shown, using these models, to play a role in tumor 
maintenance; some tumors even have “MYC addiction” (Arvanitis and Felsher, 
2006). These previous findings made using mouse models emphasize the role of 





Biological functions of MYC 
In addition to the clear role of MYC in tumorigenesis, it is a pleiotropic 
protein with various effects on normal cellular functions. The major functions of 
MYC are the regulation of cell proliferation, growth, apoptosis, and metabolism 
(Cole and McMahon, 1999; Dang, 1999). MYC is one of the first immediate-early 
genes to be characterized that is important for facilitating S phase entry from G1 
phase (Bravo, 1990). MYC promotes cell cycle progression by activating cell 
cycle-promoting factors, such as CDK4 and CDK6, and by suppressing cell cycle 
inhibiting factors, such as p21, Gadd45, and Gas1 (Gartel et al., 2001; 
Hermeking et al., 2000; Lee et al., 1997; Marhin et al., 1997; Mateyak et al., 1999; 
Wu et al., 2003). A novel mechanism whereby MYC drives G1–S cell cycle 
progression will be presented in greater detail in later chapters of this thesis.  
Another important function of MYC is the control of cell growth, which 
increases cell mass and size during normal cell development (Schmidt, 1999; 
Secombe et al., 2004). Increases in cell size have been observed during B cell 
development in transgenic mice overexpressing MYC (Iritani and Eisenman, 
1999). MYC control of cell size can occur by regulating genes involved in rRNA 
synthesis, ribosomal protein production, and other bioenergetics pathways for 
biomass accumulation which lead to cell growth (Guo et al., 2000; O'Connell et 
al., 2003; Zeller et al., 2001). MYC also regulates cellular processes, such as 
apoptosis and carbohydrate metabolism (Shim et al., 1998; Yuneva et al., 2007). 
Studies from my lab demonstrating MYC regulation of cellular glycolytic pathway 
elements have been previously reported (Kim et al., 2004).  
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In addition to the above mentioned activities, MYC has also been found to 
be one of four genes (along with Sox2, Oct4, and KLF4) that together could 
reprogram differentiated fibroblasts to pluripotent state, indicating the important 
role of MYC in maintaining cellular differentiation and preventing de-
differentiation (Singh and Dalton, 2009; Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006). 
 
Molecular mechanisms of MYC regulation 
MYC is encoded by a gene that has three exons, which can generate 
several polypeptides through the use of alternative translation initiation sites. In 
addition to protein initiation at the canonical AUG start codon, two isoforms that 
are initiated from a CUG codon in exon one and an internal AUG codon are less 
well-characterized (Blackwood et al., 1994; Hann et al., 1992; Spotts et al., 1997). 
MYC is a member of the basic helix-loop-helix family of transcription factors. It 
contains an N-terminal transcriptional regulatory domain which is followed by a 
nuclear localization signal and a C-terminal domain that includes a DNA-binding 
domain with a basic region and helix-loop-helix and leucine zipper motifs. MYC 
can heterodimerize with Max and bind DNA, and then can regulate the 
expression of target genes (Amati et al., 1993; Amati et al., 1992; Blackwood and 
Eisenman, 1991; Dang et al., 1989; Grinberg et al., 2004; Kato et al., 1992; 
Kretzner et al., 1992).  
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Two highly conserved regions, termed MYC boxes I and II, are followed by 
MYC boxes III and IV and a nuclear targeting sequence that is located within the 
N-terminal domain (Cowling et al., 2006; Dang and Lee, 1988; Kato et al., 1990; 
Pineda-Lucena and Arrowsmith, 2001). The C-terminal domain contains a basic 
HLH-ZIP domain that can dimerize with Max, a bHLH-ZIP protein, to form a 
stable heterodimer (Follis et al., 2009; Hu et al., 2005; Mustata et al., 2009). 
MYC/Max heterodimers preferentially recognize and bind to a consensus 
sequence, 5ʹ-CACGTG-3ʹ, termed E-boxes, and other non-canonical E-box 
sequences (Adhikary and Eilers, 2005; Blackwell et al., 1993; Blackwell et al., 
1990). The MYC N-terminal domain has been shown to recruit many co-factors, 
such as TRRAP, GCN5, and TBP, to form complexes (Bouchard et al., 2001; Liu 
et al., 2003; McEwan et al., 1996; McMahon et al., 2000; Vervoorts et al., 2003). 
These chromatin-modifying complexes facilitate an open chromatin structure, 
making the DNA accessible to basal transcriptional mechanisms, including RNA 
polymerase II, as well as RNA polymerases I and III (Felton-Edkins et al., 2003; 
Gomez-Roman et al., 2003; Grandori et al., 2005; Kenneth et al., 2007), resulting 
in MYC target gene activation. The main targets of MYC include genes 
associated with ribosome biogenesis, translation, metabolism, and mitochondrial 
function (Meyer and Penn, 2008; Sabo et al., 2014; Walz et al., 2014). Among 
these targets, there could be mRNAs, microRNAs (miRNAs), or long non-coding 
RNAs (lncRNAs). 
 
MYC and its selectivity 
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More recently, MYC has been proposed to function as a ‘universal’ 
amplifier of transcription (Lin et al., 2012; Nie et al., 2012). This model was laid 
out in two publications and was based on the observations that MYC can 
increase cell size and that the expression of all mRNAs are increased by MYC, 
even after accounting for differences in cell size. The two groups that published 
this model claimed that MYC appears to non-specifically amplify all transcripts, 
so they classified its effects on transcription as ‘universal’. However, two recent 
studies showed that MYC is a bona fide selective transcription factor, as 
described previously. The two groups utilized cell lines in which MYC expression 
could be induced, although cell size was not changed after MYC induction. Only 
specific genes, and certainly not all genes, were activated by MYC in these cells 
(Sabo et al., 2014; Walz et al., 2014). 
Whether MYC can directly suppress target gene transcription has also 
been called into question by the proposed amplifier model. The aforementioned 
two most recent reports have redefined the genes repressed by MYC. Miz-1, a 
MYC binding partner, was used as an example to demonstrate the role of other 
transcription factors in selecting MYC targets. MYC–Miz1 heterodimers 
specifically suppressed Miz-1 target genes (Walz et al., 2014). Additionally, the 
transcription of many MYC targets requires the binding of other transcription 
factors, such as E2F, for them to be activated (Li et al., 2003; Zeller et al., 2006). 
As previous study reported, gene loci with multiple transcription factors bound 
are more likely to be MYC-responsive in murine embryonic stem cells (Kim et al., 
2010a). Therefore, another level of selectivity rendered by these other 
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transcription factors further strengthened my supposition that MYC regulation is 
not ‘universal’ (Elkon et al., 2004). 
Moreover, among the thousands of genes bound by MYC, the degree of 
regulation is almost certainly not correlated with the expression level of MYC. 
Reasons for this could include that MYC shows varying binding affinities towards 
different chromatin configurations, and that the effects of other transcription 
factors that co-regulate MYC target genes will also affect transcription. 
 
Transcriptional repression by MYC 
The mechanism whereby MYC represses gene expression is less well 
characterized. Mad1 is both a bHLH-ZIP transcription factor and a binding 
partner of Max (Ayer et al., 1993). Mad1/Max heterodimers are able to compete 
with MYC/Max heterodimers to bind to the consensus E-box (Baudino and 
Cleveland, 2001; McArthur et al., 1998). Furthermore, Mad1/Max dimers can 
repress target gene transcription by recruiting chromatin modifying repressor 
complexes. Histone de-acetylation that results from the activities of these 
complexes could then prevent transcriptional activation at the E-box sequences 
(Ayer et al., 1995; Laherty et al., 1997; Schreiber-Agus et al., 1997). 
In addition to interactions with Mad1, MYC binding to Miz1 transcription 
factor is an important mechanism for MYC-mediated repression (Schneider et al., 
1997). For example, MYC/Max heterodimers bind to Inr element in p15INK4b 
gene and repress its transcription by disturbing Miz1 associations with the p300 
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co-activator (Seoane et al., 2001; Staller et al., 2001). Another study showed that 
Miz1 could recruit MYC to the p21 promoter. This interaction can disrupt p53 
induction of p21, thereby causing apoptosis (Seoane et al., 2002).  
MYC can also mediate gene repression by activating a cluster of 
microRNAs (miRNAs) on human chromosome 13 (Chang et al., 2008; O'Donnell 
et al., 2005). The miRNA cluster (miR-17-92 cluster) plays important roles in the 
regulation of the E2F1 and TGF-β signaling pathways (Dews et al., 2014; 
Mestdagh et al., 2010). More recently, a complex network of MYC, polycomb 
group proteins (PcGs; notably EZH2), and miRNA interactions has been 
frequently reported to underlie the mechanisms and outcomes of such 
interactions (Benetatos et al., 2014; Zhao et al., 2013). This thesis proposes a 
novel MYC-EZH2-mediated gene repression model, which will be explained in 
detail in subsequent chapters. 
Based on the studies described above, there are certain to be different 
modes whereby MYC can repress the expression of its target genes. LncRNAs 
have been implicated in facilitating this process. 
 
Long non-coding RNAs and function 
LncRNAs are a class of RNA transcripts that are larger than 200 
nucleotides (nt) and do not have apparent protein-coding potential. The human 
genome has ~25,000 protein coding genes, representing less than 2% of the 
entire genome, whereas nearly 70% of the human genome is transcribed into 
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RNA transcripts; thus, by far, most transcripts would be non-coding RNAs (2004; 
Derrien et al., 2012; Djebali et al., 2012). Compared to protein-coding mRNA 
transcripts, lncRNAs account for a large portion of the human transcriptome. 
Since the discovery of non-coding RNAs, smaller regulatory non-coding RNAs, 
such as miRNAs, have been extensively studied. By contrast, far less is known 
about lncRNAs. Indeed, for a very long time, lncRNAs have been considered to 
represent ‘transcriptional noise’. However, recent studies indicate that lncRNAs 
are involved in many normal cellular processes, as well as tumor progression 
(Batista and Chang, 2013; Grandori and Eisenman, 1997; Guttman and Rinn, 
2012; Karreth and Pandolfi, 2013; Lee, 2012; Lieberman et al., 2013; Orom and 
Shiekhattar, 2013; Oster et al., 2002; Prensner and Chinnaiyan, 2011; Ulitsky 
and Bartel, 2013). Soon after the initial cloning of lncRNAs, which identified H19 
and XIST from cDNA libraries, two studies using tiling arrays estimated that the 
number of lncRNAs is at least similar to that of protein coding genes (Bartolomei 
et al., 1991; Brown et al., 1991; Kapranov et al., 2002; Rinn et al., 2003; Rinn et 
al., 2007; Yoo-Warren et al., 1988). Technical advances in array (Gupta et al., 
2010; Rinn et al., 2007), chromatin signature analysis (Guttman et al., 2009; 
Khalil et al., 2009), computational analysis of cDNA libraries (Jia et al., 2010; 
Maeda et al., 2006), and RNA sequencing technologies (Cabili et al., 2011; Orom 
et al., 2010; Prensner et al., 2011) have revealed that thousands of lncRNAs are 
widely expressed and are under tight spatial and temporal regulation. The 
GENCODE consortium identified and validated 14,880 annotated human 
lncRNAs originating from 9277 gene loci with experimental evidence (Derrien et 
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al., 2012; Djebali et al., 2012). These findings indicate that lncRNAs are 
independent transcriptional units that have been the subject of weak selective 
pressure throughout evolution. Additionally, similarly to mRNAs, many lncRNAs 
are primate-specific, subject to histone modifications, and show tissue-specific 
expression. 
LncRNAs have a broad and diverse repertoire of functions. In the 
regulation of gene expression by lncRNAs, they function at the level of 
transcription, post-transcriptional processing, and chromatin modification (Mercer 
et al., 2009; Mercer and Mattick, 2013). One example of a lncRNA regulating 
transcription would be the repression of cyclin D1 transcription in human cell 
lines (Wang et al., 2008b). The induction of lncRNAs associated with the cyclin 
D1 promoter can be triggered by DNA damage. By recruiting the RNA-binding 
protein TLS, both CREB and p300 activities are inhibited, resulting in the 
silencing of cyclin D1 expression. Additionally, lncRNAs have been reported to 
act as co-factors that modulate transcription factor activities or regulate RNA 
polymerase II activities by interacting with the initiation complex, forming a triplex 
at the promoter (Feng et al., 2006; Martianov et al., 2007; Ohno et al., 2002). 
LncRNAs have the ability to recognize complementary sequences, allowing them 
to act in the post-transcriptional processing of mRNA because of this RNA–RNA 
specific interaction. This is exemplified by cases in which antisense lncRNAs 
mask splicing sites in mRNA, resulting alternative splicing (He et al., 2008). 
At the epigenetic level, lncRNAs can regulate the transcriptional activity of 
specific genes or entire chromosomal regions by recruiting polycomb protein 
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complexes, which are involved in chromatin modifications in either cis- or trans-
acting manners. Xist, a 17 kb X chromosome-specific non-coding transcript, 
represents one of the earliest characterized and most well-known examples, 
initiates X chromosome inactivation by coating the X chromosome and recruiting 
polycomb repressive complexes 2 (PRC2) in cis (Brown et al., 1992; Jeon and 
Lee, 2011; Zhao et al., 2008). The HOTAIR lncRNAs regulate the HoxD cluster 
of genes in trans by serving as a scaffold that enables the RNA-mediated 
assembly of PRC2 and LSD1, and facilitating binding of this complex to 
chromatin (Tsai et al., 2010). Various models have been proposed for this 
specific lncRNA function. LncRNAs contain discernable protein interaction 
domains that can recruit protein components and act as a scaffold, thereby 
assisting in the formation of unique functional complexes (Engreitz et al., 2013; 
Gupta et al., 2010; Huarte et al., 2010; Jeon and Lee, 2011; Simon et al., 2013; 
Yang et al., 2013b; Yang et al., 2011). RNA–DNA and RNA–RNA interactions 
can also be included in this process. Alternatively, lncRNAs can act as guides to 
recruit proteins, namely, the chromatin modification complexes, to target loci. 
This might occur through RNA–DNA interactions or RNA interactions with DNA-
binding proteins (Grote et al., 2013; Huarte et al., 2010; Zhao et al., 2008). 
Moreover, lncRNAs have been suggested to function as decoys that bind to 
proteins or miRNAs (Di Ruscio et al., 2013; Hansen et al., 2013; Hung et al., 
2011; Memczak et al., 2013; Poliseno et al., 2010; Tay et al., 2011; Tripathi et al., 
2010; Tripathi et al., 2013) or act as enhancers that are transcribed from an 
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enhancer region or a nearby locus to influence gene transcription (Kim et al., 
2010b; Lai et al., 2013; Li et al., 2013; Melo et al., 2013; Wang et al., 2011). 
 
LncRNAs in cancers  
LncRNA expression profiles differ dramatically between tumors and 
normal tissues. Previous large-scale RNA-seq analysis of prostate cancer tissues 
identified a group of 121 lncRNAs that showed distinguishable expression 
patterns in normal and cancerous tissues (Prensner et al., 2011). Because 
lncRNA expression patterns tend to be more tissue-specific than those of protein 
coding transcripts (Cabili et al., 2011; Derrien et al., 2012), lncRNA expression 
signatures might serve to determine the developmental lineage and tissue origin 
of human cancers with greater accuracy (Bartolomei et al., 1991; Prensner and 
Chinnaiyan, 2011; Ulitsky and Bartel, 2013). Additionally, the association of 
several lncRNAs, including MALAT-1, HOTAIR, PCAT-1, and LET, with cancer 
metastasis has been established, implying that lncRNAs could also be used as a 
biomarker for predicting cancer prognosis and survival (Gupta et al., 2010; Ji et 
al., 2003; Prensner et al., 2011; Yang et al., 2013a). Even though lncRNA 
research remains in its early stages, it is clear that lncRNAs are involved in 
regulating cell proliferation (Hung et al., 2011; Tripathi et al., 2013), cell 
differentiation (Guttman et al., 2009; Guttman et al., 2011; Kretz et al., 2013; 
Loewer et al., 2010; Ulitsky et al., 2011), cell migration (Gupta et al., 2010; Ling 
et al., 2013; Orom et al., 2010; Yang et al., 2013a), immune responses 
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(Carpenter et al., 2013; Gomez et al., 2013), and apoptosis (Huarte et al., 2010). 
Therefore, it can be hypothesized that the dysregulation of lncRNAs will 
contribute to tumorigenesis. Many lncRNAs have been shown to function as 
oncogenes or tumor suppressors. HOTAIR can trigger metastasis by its actions 
as a scaffold to link PRC2 and LSD1 (Gupta et al., 2010), thereby coordinating 
their chromatin modifying capacities. ANRIL, an antisense lncRNA of the 
CDKN2A/2B gene, represses INK4A/B expression by binding to CBX7/PRC1 and 
SUZ12/PRC2 (Kotake et al., 2011; Pasmant et al., 2007; Yap et al., 2010). Xist 
deletion results in the development of aggressive myeloproliferative neoplasms 
and myelodysplastic syndrome in female mice (Yildirim et al., 2013). 
 
MYC, lncRNA, and gene regulation 
As previously mentioned, MYC is widely recognized to be one of the most 
important transcription factors and is responsible for regulating the expression of 
a large proportion of human genes; however, the exact mechanisms of many of 
the various modes of MYC regulation remain to be fully characterized. This thesis 
aims to fill a gap in MYC target gene regulation network by adding a missing ‘link’, 
lncRNA. 
In chapter 2 of the thesis, I explore the general connection between MYC 
and lncRNAs using microarray, RNA-seq, and TCGA analyses. After validation, a 
few interesting lncRNAs are carefully examined, and I focus on DANCR 
(Differentiation Antagonizing Non-protein Coding RNA) as the one to pursue in 
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greater detail, and the use to generate a model for the combined role of MYC 
and lncRNAs in gene regulation. In Chapter 3, using several robust methods, 
such as ChIP, ChIP-seq, and further TCGA analysis focusing on DANCR, its 
validation as a bona fide MYC target is described. In chapters 4 and 5, further 
studies of the genomic and biological impacts of DANCR in human cancers are 
presented. Loss of function experiments revealed its impact on cell growth, and 
cell cycle analysis showed that growth arrest can be triggered by DANCR 
depletion that blocks the transition from G1 to S phase. Microarray gene 
expression analysis followed by GSEA (gene set enrichment analysis) generated 
a list of downstream genes that might be related to the phenotype I observed; 
among these genes, p21 was a strong candidate to be a causative gene. 
Chapter 6 describes the proposed functions of DANCR; I first introduce EZH2 by 
confirming that it is also a transcriptional regulator of p21. Then, I will propose a 
MYC-DANCR/EZH2-p21 model and prove it through a series of experiments that 
establish connections between each component of my proposed model, including 
a direct link between DANCR and EZH2, and their regulation of p21. A novel 
mode of lncRNA recognition of target genes through RNA–RNA interactions is 























Global effects of MYC on lncRNAs 
To explore the genome-wide effects of MYC on lncRNAs, I performed 
microarray and RNA-seq analyses in a human B lymphocyte cell line, P493 cells, 
in which MYC expression levels can be manipulated. P493 cells are derived from 
EREB2-5, a human B lymphocyte immortalized with the EBV viral genome and 
engineered to harbor a tetracycline (tet)-repressible MYC transgene. In the 
presence of tet, P493 cells exhibit low levels of MYC expression, whereas in the 
absence of tet, cells have high levels of MYC expression and show a morphology 
that resembles Burkitt’s lymphoma cells (Pajic et al., 2000). Cells arrest in G1 
phase after tet treatment, whereas induction of MYC upon the removal of tet 
allowed for cell cycle progression from G1 to S phase (O'Donnell et al., 2006). 
P493 cells are tumorgenic in SCID mice and can be used to generate a 
subcutaneous xenograft model for in vivo tumor formation experiments (Gao et 
al., 2007). 
I chose to use gene expression arrays as an initial approach to gain 
insights into the MYC-regulated gene network. P493 cells were treated with 0.1 
µg/ml tetracycline (Sigma) for 48 h, and then harvested alongside untreated 
control cells. Total RNA was extracted and hybridized to an Affymetrix exon array. 
The expression profiles of MYC-regulated genes were obtained. The results 
showed, as expected, that the expression of many genes was altered by 
increased MYC levels, including genes that are involved in cellular processes 
such as various metabolic pathways, cell proliferation, and mitochondrial function 
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(Meyer and Penn, 2008). For the purpose of this project, I decided to focus on 
those genes whose expression was induced by MYC. A summary of the various 
genes induced by MYC is shown in Table 1. Interestingly, two lncRNAs, DANCR 
(previously known as KIAA0114) and LOC286467, seemed to be particularly 
highly induced by MYC, especially DANCR, which was ranked 11th in the list and 
showed more than a 14-fold change in expression upon MYC induction. 
However, one limitation of gene expression arrays is the absence of 
unannotated transcripts; a large proportion of lncRNAs are still in the process of 
being annotated, and so they are not included on array chips. I next performed 
RNA-seq, which is currently the most comprehensive and unbiased technique to 
globally assess MYC regulation of the human genome. Total RNA samples were 
extracted from duplicates of high- and low-MYC P493 cells, which I made into 
libraries using a TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, 
USA) and then sequenced using an Illumina HiSeq 2000 instrument. The RNA-
seq reads were subsequently aligned to the human genome using Tophat 
(Trapnell et al., 2009). Unsupervised hierarchical clustering showed patterned 
variations in the expression of transcripts that were either induced or repressed 
by MYC (Figure 1). Again, in this thesis, I focused on the genes that were 
induced by MYC. By arbitrarily setting a cut-off threshold at a 2-fold expression 
change after MYC induction, I found that 3582 transcripts remained, including 
386 non-coding RNA transcripts, among which 230 were lncRNAs (Figure 2). 
After a closer examination of the top portion of this list of lncRNAs, I discovered 
that DANCR (annotated as ‘SNHG13” in this list) was once again ranked 2nd of all 
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MYC regulated lncRNAs with a 12-fold change, and SNHG4 was the only 





















Table 1. MYC-induced genes identified by gene expression array analysis. 
MYC-induced genes ranked by fold-change (expression difference) between Hi- 
and Low-Myc conditions in P493 cells, generated using gene expression arrays. 
The two highlighted ‘genes’ are the top two lncRNAs identified based on MYC-


















Figure 1. MYC-regulated gene clusters. A heat map showing unsupervised 
hierarchical clustering of expression values of MYC-regulated gene clusters for 
Hi- vs. Low-MYC states in P493 cells. RNA-seq was performed for RNAs derived 
from four independent experiments. Each column represents an experiment and 
each row indicates a group of similarly expressed genes. Transcripts were 
divided into 30 groups based on MYC responsiveness, which is represented on a 
red-yellow color scale. On the right side of the figure, the first smaller number in 
is the group number, and the second number indicates the number of transcripts 



































































Figure 2. The number of lncRNAs induced by MYC. A pie chart representing 
the proportions of MYC-induced non-coding sequences and lncRNAs among all 
MYC-induced transcripts showing at least a two-fold expression change. The 
numbers indicate the results from a RNA-seq experiment in P493 cells. 
  
386  Non-Coding RNAs 
3582 MYC induced transcripts 






Table 2. MYC-induced genes identified using RNA-seq. A list of the top MYC-
induced lncRNAs ranked by fold-change (expression difference) between Hi- and 
Low-Myc conditions in P493 cells was generated based on RNA-seq data. 
Notably, SNHG13 is an alternative name for DANCR. Some of the lncRNA 
annotations in the table are named as known coding genes, but they are actually 





Validation of microarray and RNA-seq data 
To validate my microarray and RNA-seq data, I performed quantitative 
real-time PCR analysis. I chose to analyze three of the previously mentioned 
possible MYC targets (DANCR, SNHG4, and LOC286467) using pre-validated 
primers. LOC286467 was found to have ~26 fold-changes and SNHG4 had over 
40 fold-changes between Hi- and Low-MYC conditions in P493 cells (Figure 3). 
For DANCR, that fold-change was ~36-fold in P493 cells, and ~6-fold in PC3 
cells (Figure 4), a cell line that I will introduce and discuss in detail in later 
chapters. The 6-fold change was probaby a consequence of inefficient MYC 
siRNA knock-down in PC3 cells compared with the more efficient tetracycline-
regulated MYC in P493 cells. Taken together, the expression of all three 
lncRNAs were validated to be markedly induced by changes in MYC levels. 
 
TCGA analysis of lncRNAs in cancer 
To further investigate the role of lncRNAs and their connections with MYC 
in real life cancers, I collaborated with the lab of Lin Zhang at University of 
Pennsylvaina to analyze The Cancer Genome Atlas (TCGA) data. We retrieved 
RNA-seq profiles from 4015 specimens across 11 cancer types, along with 350 
corresponding normal control specimens across 7 matching tissue types from 
TCGA. A heatmap was generated for MYC/lncRNAs correlations, and, 
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interestingly, DANCR was found to show increased expression in the high MYC-
epxressing primary tumors samples mentioned above (Figure 5). 
 
MYC/DANCR co-expression analysis in primary cancers 
To probe the role MYC regulation of DANCR in cancer tissues, we used 
the co-expression analysis method (described in the methods section), which is 
also known as guilt-by-association (GBA) analysis. GBA analysis for DANCR 
was performed for the RNA-seq data to identify the most significantly positive 
and negative co-expressed protein-coding mRNAs in breast and prostate 
cancers. When I ‘zoomed in’ on MYC/DANCR correlations, I found that in both 
breast and prostate cancers, MYC and DANCR are co-expressed with a R2 value 
of 0.22 or 0.23 in breast and prostate cancers, respectively, and these 
correlations were statistically significant (P<0.00001 P=0.00003, respectively; 
Figure 6). 
The evidence I have obtained to date all point to DANCR being one of the 
most highly regulated MYC-dependent transcripts, including both coding and 
non-coding transcripts. The tight regulation of DANCR by MYC in vitro and ex 
vivo in tumors, combined with a recent report in which DANCR was shown to be 
down-regulated during cell differentiation and required to enforce the 
undifferentiated cell state (Kretz et al., 2012), suggests that it must confer 
significant functional importance, which will be characterized in later chapters. 
Additionally, I carried out preliminary experiments to study the biological 
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importance of LOC286467 and SNHG4, although I observed no phenotypes 
associated with these two transcripts (data not shown). Thus, I will only focus on 






























Figure 3. qRT-PCR validation of the induction of lncRNA expression by 
MYC. This experiment was performed in P493 cells. Bar graphs represent the 
mean mRNA levels from triplicate samples. Error bars represent the standard 






















































Figure 4. qRT-PCR validation of the induction of DANCR by MYC. Bar 
graphs represent the mean mRNA levels from triplicate samples. Error bars 
represent the standard deviation (n = 3). Experiments were performed in (A) 





































































Figure 5. A heatmap of lncRNAs that are co-expressed with MYC. The 
heatmap generated from an analysis of TCGA RNA-seq data. MYC expression is 
depicted at the top as reads per kb per million (RPKM). Each column represents 
a single clinical sample, and each row represents a lncRNA. From top to bottom, 
lncRNAs are arranged in the order of high to low expression values in a sample, 
which represented using a red–green color scale. DANCR is one of the top MYC 





















Figure 6. Correlations between MYC and DANCR expression in breast and 
prostate cancers. Graphs were generated from TCGA RNA-seq data from 
breast (n = 1096) and prostate (n = 256) cancer tissues. Guilt by association 
(GBA) analysis of TCGA RNA-seq data was performed in collaboration with Dr. 


















   
   
   










Materials and Methods 
Cell culture 
P493 cells were a generous gift of Prof. D.Eick at the Institute of Clinical 
Molecular Biology and Tumors Genetics, GSF-Research Centre, Munich, 
Germany. The PC3 cell line was obtained from the American Type Culture 
Collection (ATCC). Cells were cultured in RPMI 1640 with 10% fetal calf serum 
(FCS) and 1% penicillin/streptomycin. To repress MYC expression, cell cultures 
were supplemented with 0.1 µg/ml tetracycline (Sigma) for 48 h and harvested. 
 
Microarray hybridization and analysis  
At 48 h after tetracycline treatment, samples were processed by the Johns 
Hopkins Medical Institutions Deep Sequencing & Microarray Core Facility. RNA 
samples from these cells were used to probe an Affymetrix 1.0 ST exon array. 
Total RNA was isolated from cells using a RNeasy Plus Mini Kit (Qiagen) 
according to the manufacturer’s instructions. Approximately 5 µg per chip of 
fragmented and labeled cDNA was hybridized to the array. Fluorescence was 
detected using an Affymetrix GeneChip Scanner. Analysis was carried out using 







Total RNA from cells was extracted using TRIzol (Invitrogen) and a RNeasy Plus 
Mini Kit (Qiagen). Extracted RNA samples underwent quality control (QC) 
assessment using an Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA) and all 
RNA samples that were submitted for sequencing had an RNA Integrity Number 
RIN) >9, with a minimum of 1 µg input RNA. Poly-A library preparation and 
sequencing were performed at the Penn Next Generation Sequencing Core 
following standard protocols. Briefly, I started with total RNA, and mRNA was 
purified using poly(A) selection or rRNA depletion before the RNA was 
chemically fragmented and converted into single-stranded cDNA using random 
hexamer priming. Next, the second strand was generated to create double-
stranded cDNA. Library construction began with the generation of blunt-end DNA 
fragments from ds-cDNA. Then, A-bases were added to blunt-ends to prepare 
them for the ligation of sequencing adapters using the TruSeq RNA Sample 
Preparation Kit (Illumina). Fragments of ~300 to ~400 bp were selected by gel 
electrophoresis, followed by 15 cycles of PCR amplification. The prepared 
libraries were then sequenced using an Illumina HiSeq 2000, which generated 
~50 to ~100 million unfiltered reads per sample. RNA-seq data were aligned to 






Quantitative real-time PCR (RNA quantification) 
Total RNA was extracted from cells using a RNeasy-plus Mini Kit (Qiagen) 
according to the manufacturer’s instructions. RNA concentrations and quality 
(A260/280 between 1.9 and 2.1) were determined using a Nanodrop. Then, 1–2 µg 
RNA was reverse transcribed to cDNA using the Taqman-based reverse 
transcription. Quantitative RT-PCR was carried out using Power SYBR Green 
PCR Master Mix (Applied Biosystems) with a StepOnePlus™ Real-Time PCR 
System (ABI). Melting curve analysis was performed at the end of each run and 
all PCR reactions were performed in triplicate. The relative amount of each gene 
of interest was calculated using the ΔΔCt method. Sequence-specific primer pairs 
were designed to cross exon–exon junctions.  
 
TCGA analysis 
To analyze expressional aberrations of lncRNA in human cancers, we retrieved 
RNA sequencing (RNA-seq) profiles of 4015 human tumor specimens across 11 
cancer types and 350 corresponding normal control specimens across seven 
types of matching tissues from TCGA. Initially, we identified ~2000 manually 
annotated lncRNA genes and calculated the RPKM (reads per kilobase per 
million mapped reads) for each lncRNA gene. The log-transformed median 
center of the RPKM values that correspond to a given lncRNA gene was used to 
represent the normalized expression level of that lncRNA. 
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Recently, a bioinformatic approach, termed guilt-by-association (GBA) analysis, 
has been used to gain a global understanding of lncRNAs and protein-coding 
genes that are significantly co-expressed and, thus, presumably are correlated. 
Briefly, the GBA approach using gene co-expression analyses can identify 
protein-coding genes and pathways that are significantly correlated with a given 
lncRNA. This work was performed in collaboration with the laboratory of Lin 



































As described in previous chapters, MYC regulates cell growth, 
proliferation, metabolism, and apoptosis, as well as the transcription of a large 
proportion of all human genes. However, within its complex target gene network, 
MYC can affect certain target genes more than others. By identifying these 
critical points or nodes, I can better understand the network whereby MYC can 
regulate cellular processes, including dysregulated proliferation in cancer. As 
lncRNAs are emerging as an important mediator of biological functions in cells, 
herein I attempted to identify key MYC-regulated lncRNAs that are part of this 
network. Additionally, by exploring the MYC-DANCR relationship, I aim to 
establish a model of MYC pathways and to identify its critical lncRNA targets.  
The large-scale microarray and RNA-seq experiments described in the 
last chapter showed that DANCR demonstrates great, if not the greatest, MYC-
induced responsiveness among all lncRNAs. In this chapter, I sought to 
determine whether DANCR is directly regulated by MYC by testing MYC binding 
to the genomic DANCR locus. 
 
Chromatin immunoprecipitation to validate DANCR as a direct MYC target 
Although DANCR mRNA transcript levels can be positively regulated by 
MYC, whether DANCR is a direct or indirect MYC target has not yet been fully 
established. I used chromatin immunoprecipitation (ChIP) to determine where 
MYC binds within target genes (Zeller et al., 2001). The tendency of MYC to bind 
to phylogenetically conserved canonical E boxes, 5ʹ-CACGTG-3ʹ, in the promoter 
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or intron 1 of target genes has been observed previously (Haggerty et al., 2003; 
Zeller et al., 2003). To extend these findings, I conducted a detailed analysis of 
DANCR genomic sequences. In this analysis, I localized possible MYC binding 
sites in the DANCR promoter region, which contains a canonical E box sequence 
and designed primers to cover that region. As negative controls, I carried out 
ChIP using a control IgG in place of anti-MYC antibody, and I also amplified an 
intergenic locus region with no previously known binding to MYC as an additional 
negative control. ChIP assays were carried out in P493 cells, PC3 cells, and 
human embryonic stem cells (H1 and H9), followed by quantitative real-time PCR. 
As expected, DANCR promoter regions showed high levels of MYC binding 
relative to both IgG controls and to negative control regions in all cell lines 
examined (Figures 7 and 8). 
 
The pattern of MYC binding to the DANCR promoter in various cell types 
Furthermore, using publicly available Encode ChIP-seq data from UCSC 
genome browser, I first examined the temporal MYC–DANCR binding patterns in 
P493 cells. There appeared to be three binding sites for MYC along the DANCR 
genomic sequences, with the one containing the E-box sequence being the 
strongest.  However, upon closer examination, I observed no MYC binding after 
tetracycline treatment (to induce MYC depletion), but MYC binding to the E-box-
containing site was recovered as early as 1 h after tetracycline removal, and 
MYC binding to all three sites was recovered 24 h after tet removal (Figure 9). By 
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contrast, some MYC targets, such as NPM1, exhibit weak MYC binding, even 
after tet treatment, possibly because of endogenous MYC activity and leakiness 
of the engineered MYC-responsive unit. These observations suggest that MYC–
DANCR binding is more sensitive to MYC levels than some of the other MYC 
targets. MYC was also found to bind specifically (with definite peaks) in the 
vicinity of the DANCR promoter region in GM12878, HeLa, Hep02, HUVEC, 
K562, and MCF7 cells (Figure 10). 
In summary, these in vitro data indicate that MYC binds to a canonical E-
box sequence in the promoter region of DANCR, and establish that DANCR is a 













                 
                                 
Figure 7. Chromatin immunoprecipitation validation of DANCR as a direct 
target of MYC. CHIP validation of MYC binding to the DANCR promoter region 
in P493 and PC3 cells. Quantitation of MYC binding by real-time PCR analysis 
(expressed as the fold-change over IgG), a negative intergenic region that is 
dozens of kb away from the DANCR promoter region was selected as another 
negative control. Error bars indicate standard deviation (n = 3). (A) P493 B-cell 































































Figure 8. Chromatin immunoprecipitation validation of DANCR as a direct 
MYC target in human embryonic stem cells. CHIP validation of MYC binding 
to the DANCR promoter region in hES cells. Quantification of MYC binding by 


























                
                       
  
 








Figure 9. CHIP-seq data-based assessment of MYC–DANCR and MYC–NPM1 
binding. Binding of MYC is shown at different time points in P493 cells. MYC 
binding to the DANCR and NPM1 promoters at 0, 1, and 24 h after tetracycline 
release is shown. The hg19 genome assembly, obtained from publicly available 




















Figure 10. MYC binding to the DANCR promoter in six different cell types. 
Data shown above were obtained from publicly available data at 









Materials and Methods 
Cell Culture  
P493 and PC3 cells were cultured as described in Chapter 2. The hES cells were 
maintained by Dr. Karen Zeller in the Dang lab. Briefly, hES cells (H1 and H9 
clones) were grown on mouse embryo fibroblasts (MEFs) in culture medium that 
consisted of 80% DMEM/F12 supplemented with 20% knock-out serum 
replacement (Invitrogen), 1 mM L-glutamine, 0.1 mM 2-mercaptoethanol, and 1% 
nonessential amino acids (Sigma–Aldrich). 
 
Chromatin Immunoprecipitation 
ChIP was performed using a Imprint Ultra Chromatin Immunoprecipitation Kit 
(Sigma–Aldrich), following the manufacturer’s protocol. Briefly, cells were cross-
linked in 1% formaldehyde for 10 min at room temperature, after which the 
reaction was stopped adding glycine to a final concentration of 0.125 M. Cells 
were scraped, collected, and then rinsed twice with PBS. Cells were then lysed in 
‘swelling buffer’ and the nuclei were extracted. Nuclear lysis buffer was used to 
lyse nuclei and sonication (30 sec intervals between each 30 sec sonication at 3 
× 10 min) was performed afterwards. Sonicated DNA was blocked with Staph A 
beads and salmon sperm DNA, followed by overnight immunoprecipitation with 
anti-MYC antibody (sc-764, Santa Cruz Biotechnology) or IgG control. Staph A 
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beads were used to ‘pull-down’ the complexes. Extensive washes were then 
carried out. The antibody–protein–DNA complexes were eluted from Staph A 
beads by vortexing. De-crosslinking was performed by adding NaCl and then 
heating overnight at 65ºC, followed by RNase A and Proteinase K treatment. 
Finally, DNA was eluted and analyzed by quantitative real-time PCR. 
 
Quantitative real-time PCR (ChIP validation) 
Quantitation of chromatin IP fragments was performed as described above using 
Power CYBR Green PCR master Mix (Applied Biosystems) according to 
manufacturer’s instructions. The relative amounts of each ChIP sample were 
determined using the ΔΔCt method and data were presented relative to the IgG 
signal. Alternatively, known quantities of 10-fold dilutions of total input DNA were 
used to generate standard curves for each primer pair. The relative amounts of 
each ChIP sample (expressed as the percentage of total input) were determined 
in the linear range according to the respective CT values. For each primer set, 






















Once I established DANCR to be a direct MYC target and one of the most 
highly MYC-induced transcripts, I explored whether DANCR plays a role in 
human cancers and how its expression might be related to MYC expression. 
Furthermore, to study the biological functional significance of DANCR in cancer, 
it was important to extend my studies beyond the P493 cell system. Specifically, 
P493 cells are not amenable for investigation with certain methodologies that the 
Dang lab frequently utilizes, including RNA interference (RNAi). Thus, I turned 
my attention to another cancer type, prostate cancer, for most of the following 
functional studies. I will lay out my rationale for that decision later in this chapter. 
Herein, I provide evidence that DANCR is up-regulated in most primary 
cancers to varying degrees, particularly in prostate cancers. 
 
DANCR in human cancers 
To evaluate DANCR expression profiles in cancer tissues ex vivo, I first 
considered the oncomine database, which is an excellent tool for examining gene 
and transcript activities in a certain type of cancer or across multiple cancer types. 
Oncomine is a comprehensive expert-curated cancer database that can help 
determine the expression profiles of selected gene(s) across 41 cancer types, 
tissues, perturbations, treatments, or other clinical parameters. Therefore, I used 
it for a quick search of DANCR expression profiles across all available cancer 
types, and the results obtained are displayed in Figure 11. In brief, in most of the 
primary human cancers DANCR expression was consistently upregulated in 
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contrast to normal tissue counterparts. As shown in Figure 11, Burkitt’s 
lymphoma, prostate cancers, and colon cancers were chosen as representative 




















Figure 11. DANCR expression profiles of tumor versus normal tissue (from 
Oncomine.org). Median DANCR expression levels in either tumor or normal 
samples are represented by bar graphs. (A) Prostate cancer (n=13) vs. normal 
tissues (n=8); (B) Burkitt’s lymphomas (n=5) vs. normal tissues (n=5 each); and 









MYC expression in prostate cancer 
Prostate cancer is the most frequently diagnosed male cancer, and the 
second most common cause of death from cancer in men. In the United States, 
over 230,000 men will be diagnosed with prostate cancer and ~30,000 will die 
from it in the year 2014 (Siegel et al., 2014). Activation of the MYC oncogene 
frequently occurs in aggressive prostate cancers; hence I was interested in the 
potential role of DANCR in prostate cancer. Elevated expression of MYC in 
prostate cancer is generally a consequence of gene amplification and increased 
expression owing to high-risk single nucleotide polymorphisms near the MYC 
gene on 8q24 (Al Olama et al., 2009; Eeles et al., 2008; Eeles et al., 2013; 
Hazelett et al., 2014; Yeager et al., 2007). As shown in Figure 12, prostate 
cancer is one of the top MYC-driven cancers in terms of the level of alterations in 
MYC copy number (amplifications), as alterations occurred ~20% of the time as 
shown by TCGA analysis. Furthermore, MYC is activated at the earliest phases 
of prostate cancer (e.g., in tumor-initiating cells). MYC contributes to disease 
initiation and progression by stimulating an embryonic stem cell-like signature, 
which is partially characterized by repressing cell differentiation. Finally, 
overexpression of MYC alone is sufficient to immortalize primary human prostate 
epithelial cells in vitro, and the overexpression of MYC alone in vivo might be 
sufficient to transform prostatic epithelial cells into PIN cells (Koh et al., 2010) 
(Figure 13). Considering these findings together, I have demonstrated the 
important role of MYC in prostate cancer, and show that prostate cancer is a 
MYC-driven cancer. As prostate cancer is amenable to experimental 
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manipulation, it represents a suitable system to study MYC–DANCR interactions 

































       Prostate Cancer 
Figure 12. MYC copy number alterations in primary tumors. Primary tumors 
are ranked by the frequency of alterations in MYC DNA copy numbers that were 
obtained from the cBioPortal TCGA database. Bars indicate the frequency of 













                                                                                        Koh et al., 2010 
Figure 13. Photomicrographs from 4-week-old Low-MYC mice. (A) H&E 
showing of two populations of acini. Left, normal histology; right, high-grade PIN. 
(B) Immunohistochemical staining for MYC shows that morphologically 




DANCR in prostate cancer 
By selecting human prostate cancer as our main system, which is critically 
driven by MYC activity, I sought to determine whether DANCR is up-regulated in 
prostate cancer. I compared 20 paired normal versus tumor prostate tissue 
samples (each pair was collected from the same patient) from Dr. Angelo De 
Marzo at Johns Hopkins Medical Institutions. Then, I performed quantitative real-
time PCR for MYC and DANCR for validation, and I found that MYC and DANCR 
expression were consistently elevated in every single tumor tissue compared to 
its accompanying normal paired tissue sample (Figure 14). I also assessed the 
correlation of elevated levels of expressions between MYC and DANCR for each 
pair, and observed no concordant pattern within these 20 pairs; this could be 
attributed to other factors that affect their expressions in vivo. 
It is also notable that based on our analysis of MYC–DANCR interactions 
on patient survival (Figure 15), higher MYC expression clearly indicated a poorer 
outcome in prostate cancer patients (P = 0.007). It appears that high DANCR 
expression showed a trend toward a poorer outcome in prostate cancer 
(although this did not reach statistical significance, P = 0.11). I can tentatively 
conclude that higher expression of DANCR is likely associated with a poorer 
outcome in prostate cancer patients, and that DANCR expression could 








Figure 14. MYC and DANCR expression in 20 paired prostate tumor and 
normal tissues. Expression levels in tumor tissues are shown as fold-changes 
compared to the levels in the paired normal tissue. (A) Bar graphs represent 
MYC mRNA transcript level (fold-change) in the tumor sample compared to the 
paired normal tissue. (B) Bar graphs represent DANCR mRNA levels (fold-
change) in tumor samples compared to the paired normal tissue. Paired tumor 






























































Figure 15. Kaplan–Meier curves for prostate cancer survival. Poorer survival 
outcomes and higher MYC and DANCR expression levels correlated in prostate 
cancer patients (n=256). Data were obtained from TCGA. P = 0.0072 and 0.11 
for MYC and DANCR, respectively. (A) MYC. (B) DANCR.  
  
A B MYC DANCR 
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Materials and Methods 
Survival analysis 
Kaplan–Meier survival curves were generated using Cutoff Finder software 
(Budczies et al., 2012) with an arbitrarily selected RPKM cut-off of 58.14 or 43.92 
for MYC or DANCR, respectively. 
 
Quantitative real-time PCR (RNA quantitation) and TCGA analysis were 










Elucidating the functional significance and 




Having established that DANCR is a direct MYC target that is globally 
elevated in human cancers, I explored the biological functions of DANCR in 
cancer and how it fits into the MYC-regulated gene network. 
 In this chapter, I use methods, such as RNAi, cell cycle analysis, 
microarray analysis, and morpholino oligos, to study the biological role of 
DANCR in human cancers. I propose a new mode of gene regulation by MYC, 
which occurs through lncRNAs or, in this chapter, DANCR. 
 
DANCR is required for cellular proliferation and cell cycle progression in 
prostate cancer cells 
Based on the knowledge that DANCR is a MYC target and that its levels 
are globally increased in human cancers, especially in prostate cancer, I next 
sought to directly determine whether DANCR is necessary for MYC-mediated 
cellular proliferation. I carried out small-interfering RNA (siRNA)-mediated 
depletion of DANCR in two different human prostate cancer cell lines, DU145 
and PC3 cells. I designed siRNA duplexes (three DANCR siRNAs, K97–K99, that 
targeted different regions of the transcripts and one MYC siRNA) to inhibit the 
expression of DANCR and MYC (as a positive control), and introduced these 
siRNAs into cells by Lipofectamine 2000-assisted transfection. To monitor 
transfection efficiency, DNACR expression was assessed by qRT-PCR. 
Transfection of all three siRNAs that directly targeted DANCR resulted in ~80–90% 
reduction of DANCR expression 48 and 72 h post-transfection, whereas siRNA 
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transfection against MYC resulted in 60–80% reduction of DANCR expression at 
similar time points (Figures 16B and 17B). Compared to control cells transfected 
with a non-targeting (NT) pool of ‘scrambled’ siRNAs, DANCR- and MYC-
depleted prostate cancer cells exhibited markedly reduced rates of cell 




             
 
              
 
Figure 16. The effects of DANCR and MYC siRNA-mediated depletion on the 
proliferation of DU145 prostate cancer cells. (A) The rates of cellular 
proliferation were reduced after depletion of DANCR and MYC. Cells were 
transfected with a non-targeting (NT) siRNA pool as a control. Line graphs 
represent mean cell numbers, error bars represent standard deviation (n = 3). (B) 
qRT-PCR RNA quantitation of DANCR for siRNA-mediated DANCR and MYC 
knock-down; bar graphs represent mean DANCR mRNA expression 48 and 72 h 
post-transfection relative to NT siRNA-transfected cells; error bars represent 


































































               
 
 
   
 
 
Figure 17. The effects of depleting DANCR and MYC on the proliferation of 
PC3 prostate cancer cells. (A) Rates of cellular proliferation were reduced after 
the depletion of DANCR and MYC. Control cells were transfected with a non-
targeting (NT) siRNA pool. Line graphs indicate mean cell numbers; error bars 
indicate standard deviation (n = 3). (B) qRT-PCR RNA quantification of DANCR 
for siRNA-mediated DANCR- and MYC-knock-downs; bar graphs represent 
mean DANCR RNA expression 48 and 72 h post-transfection relative to NT 



























































Because there was no apparent increase in apoptosis based on 
morphological observations, I next carried out cell cycle analysis to pinpoint 
where in the cell cycle DANCR acts to trigger cell proliferation arrest. By double-
labeling PC3 and DU145 cells with a synthetic nucleoside, Bromodeoxyuridine 
(BrdU), and DNA-binding dye, 7-Aminoactinomycin D (7AAD), the cell cycle 
profile of the population with low DANCR expression was compared to the 
control cell population (Figure 18A). Depletion of DANCR resulted in significant 
G1/S phase entry blockade, as the frequency of cells in S phase was 34% of 
cells among DANCR-positive populations, compared to 11% among DANCR-
negative populations. Similar observations were made in DU145 cells (Figure 
18B).  
As mentioned in Chapter 2, for negative-control purposes, I also silenced 
two MYC target lncRNAs, SNHG4 and LOC286467; however, successful 
depletion of both targets did not affect PC3 or DU145 cell proliferation (data not 
shown). The findings that I presented in this chapter demonstrate that DANCR 
expression is necessary for progression through the G1/S phase transition and 





















Figure 18. Cell cycle analysis of DANCR knock-down versus control siRNA 
in PC3 and DU145 cells. Flow cytometry profiles showing DNA content (7-AAD 
staining) on the x-axis and DNA synthesis (indicated by BrdU incorporation) on 
the y-axis. 
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DANCR depletion alters downstream gene expressions 
To gain further functional insights into the mechanisms whereby DANCR 
and MYC affect cancer cell biology, I performed genome-wide mRNA expression 
profile analysis on PC3 cells after siRNA-mediated depletion of DANCR and 
MYC. PC3 cells were transfected with DANCR and MYC siRNA, and then were 
harvested after 72 h. Total RNA was extracted and hybridized to Affymetrix exon 
1.0 ST array. Triplicate experiments were performed. As a result, upon DANCR 
knock-down, my DNA microarray study of Low-DANCR cells indicated that 526 
genes showed increased levels of expression with a two-fold cut-off compared to 
control cells. I selected up-regulated genes to test the hypothesis that DANCR 
plays a vital role in gene repression. I then applied gene set enrichment analysis 
(GSEA) on the 526 genes, and found that 112 of these 526 genes overlapped 
with genes that were reported to be down-regulated by EZH2 by another 
research group (Nuytten et al.). This list of EHZ2 down-regulated genes was 
based on two previously performed microarray analysis in which EZH2 was 
knocked-down in the same cell line that I used, PC3 cells. Additionally, the large 
number of overlapping genes was quite remarkable, so I decided to focus on 
EZH2. A partial summary of the GSEA results are shown in Figure 19.  
As part of the PRC2 polycomb repressive complex, EZH2 is a histone 
lysine methytransferase that catalyzes the tri-methylation of histone 3 on lysine 
27 (H3K27me3), which has been shown to be involved in chromatin remodeling 
and subsequent gene silencing (Simon and Lange, 2008; Sparmann and van 
Lohuizen, 2006). The remarkable number of overlapping genes from GSEA as 
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well as the important gene regulatory function of EZH2 carries out suggest that it 
might play a role in MYC–DANCR-mediated gene regulation. Hence, I decided to 
test the hypothesis that EZH2 is directed by DANCR to suppress specific target 
genes. 
When I also considered the MYC knock-down expression data to rule out 
false positive targets, 230 out of 526 genes remained, including 61 genes that 
overlapped with the EZH2 down-regulated gene list. In collaboration with Dr. 
Hongkai Ji, a biostatistician from Johns Hopkins School of Public Health, I 
reanalyzed the raw data from these DANCR- and MYC-depletion microarrays, 
along with the EZH2-depletion array data from the other research group. The 
process for this analysis is shown in Figure 20. The final analysis yielded a list of 
77 commonly up-regulated genes that appeared to be affected by all the 
depletion of these three regulators, DANCR, MYC, and EZH2 (Table 3). 
To validate my microarray and bioinformatics analyses, I selected eight genes 
from top of the list based on their cell cycle regulatory or cancer related functions. 
I first performed quantitative real-time PCR analysis for expressional difference 
validation 72 h after DANCR knock-down using pre-validated primer sets. Then, I 
carried out EZH2 ChIP-qPCR for the preliminary validation of these genes as 
bona fide EZH2 targets. In summary, I confirmed the up-regulation of all eight 
genes by DANCR knock-down, which ranged from 2- to 8-fold. Additionally, all 
eight genes demonstrated fold-enrichments at their promoter regions for EZH2 
binding from 2- to 9-fold relative to IgG. I compiled the results of these validations 






















Figure 19. Gene set enrichment anaylysis (GSEA) against previous 
expression profiling experiments available in public databases. Top panel, 
names of the overlapping genes. Right side, a list of previous experiments that 
showed genes that overlapped with my list, which were ranked by the number of 
overlapping genes from large to small. Highlighed block, overlapping gene from 
both lists. This analysis revealed a large overlap between selected genes that 
were up-regulated upon DANCR knock-down and those that were increased 



























Figure 20. Illustration of the process for identifying candidate genes 
affected by DANCR, MYC, and EZH2. Venn diagrams represent a comparison 
of DANCR, MYC, and EZH2 responsive genes.   

























Table 3. Genes that are commonly up-regulated by MYC, DANCR, and EZH2 
knock-down. Only the top part of the 77 genes list is shown above. Yellow 





Table 4. Validation of targets regulated by both DANCR and EZH2 in PC3 
cells. Left column, fold-induction by DANCR depletion for each gene; total 
mRNA was isolated 72 h after transfection of DANCR siRNA. Right column, fold-
enrichment of EZH2 binding compared to IgG for each gene promoter locus.  
  
 Expression fold 
change (DANCR kd / 
nt control) 
Fold enrichment 
(EZH2 ChIP / IgG 
ChIP) 
TNFAIP3 ~4-fold ~3-fold 
SLC16A2 ~3-fold ~2-fold 
SERPINE1 ~2-fold ~3-fold 
BMF ~8-fold ~9-fold 
HMOX1 ~4-fold ~3-fold 
PIP4K2A ~3-fold ~4-fold 
CTSB ~3-fold ~2-fold 
CDKN1A ~5-fold ~5-fold 
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DANCR regulates p21 
Among the eight validated genes, CDKN1A (p21) immediately caught my 
attention because it is an important G1/S cell cycle regulator. Its regulation by 
DANCR is consistent with the G1/S phase arrest phenotype that I observed after 
DANCR depletion. 
CDKN1A encodes p21, also known as cyclin-dependent kinase inhibitor 1 
or CDK-interacting protein 1, and p21 binds to and inhibits the activity of the 
CDK2, CDK1, and CDK4/6 complexes. By doing so, it functions as a regulator of 
cell cycle progression at G1. Additionally, p21 was previously found to mediate 
p53-dependent cell cycle phase arrest in G1 in response to a variety of stress 
stimuli, to promote cellular differentiation, and to prevent cell proliferation (el-
Deiry et al., 1993; Gartel and Radhakrishnan, 2005; Harper et al., 1993; Xiong et 
al., 1993). My own TCGA analysis indicated that a poor prognosis is significantly 
associated with p21 expression in prostate cancer (P = 0.01), suggesting its 
important biological role in human cancers (Figure 21). 
Previous qRT-PCR analysis demonstrated a five-fold up-regulation of p21 mRNA 
levels in DANCR siRNA-transfected cells 72 h after treatment compared to NT 
siRNA-transfected control cells. Immunoblot analysis further confirmed the 
increased levels of p21 protein (Figure 22). These findings confirm that DANCR 





                 
Figure 21. Poor survival outcome correlates with p21 expression in 
prostate cancer patients. Data obtained from TCGA (n = 256). A p21 
expression cut-off was set at 12.17 RPKM with (P = 0.01). RPKM, reads per 



















Figure 22. Depletion of DANCR by RNAi activates p21. (A) p21 mRNA 
transcript fold-changes in expression. (B) Immunoblot of p21 and tubulin (a 
loading control) protein levels after DANCR depletion. Cell lysates were analyzed 








Lastly, I used the co-expression analysis method with TCGA RNA-seq 
data to examine the relationship between DANCR and p21 in human cancers. I 
found that in both prostate and breast cancers, DANCR and p21 were 
significantly negatively co-expressed with R2-values of –0.23 and –0.137, 









Figure 23. Negative correlation between DANCR and CDKN1A (p21) 
expression in prostate cancer. Levels of mRNA transcripts were compared (n 





















Figure 24. Negative correlations between DANCR and CDKN1A (p21) 
expression in breast cancers. TNBC, Triple-negative breast cancer (n = 1096); 






All Breast Cancers            TNBC               Non-TNBC 
R2 = –0.137 
P < 0.000011 
R2 = –0.147 
P < 0.09 
R2 = –0.125 





















DANCR suppresses p21 in other cell types 
As mentioned in Chapter 1, P493 cells are not very amenable to siRNA 
treatment. However, morpholino oligo technology offers an alternative DANCR 
knock-down strategy for P493 cells. 
Morpholinos are anti-sense oligos that can block sites on RNA and 
obstruct cellular processes. A morpholino oligo specifically binds to its selected 
target site and blocks access by cell components for that target site. A 
morpohlino can be used to block translation, splicing, miRNAs, miRNA targets, or 
ribozyme activity (Heasman, 2002; Konig et al., 2007; Matter and Konig, 2005). 
The DANCR transcript has two introns, I designed two vivo-morpholinos to 
target the two intron–exon junctions and named them DANCR 1 and DANCR 2 
for intron 1 and intron 2 targeting, respectively. As shown in Figure 25A, I tested 
three different concentrations (0.5, 1.0, and 1.5 µM) of morpholinos treatments 
for 48 h, and I found a predictable dose-response, as the severity of the 
phenotype triggered corresponded to the amount of morpholino that I put in. In 
summary, I found that all three concentrations of morpholinos caused reductions 
in cell proliferation. When the morpholino concentration was increased, a greater 
reduction in cellular proliferation was observed; the 1.5 µM concentration of 
morpholino yielded the most severe growth reduction and the greatest 
suppression of DANCR RNA. Additionally, DANCR 1 appeared to more 







           
 
 
Figure 25. The effects of two vivo-morpholinos that depleted DANCR on the 
proliferation of P493 cells. (A) Rates of cellular proliferation were reduced after 
DANCR depletion. A total of three different concentrations of morpholinos were 
tested (0.5, 1.0, and 1.5 µM) with standard control morpholino (Std) treatment 
and untreated samples as controls for 48 h. (B) Bar graphs indicate the DANCR 
RNA levels after treatment with mopholino at different concentrations. Std, 













































































I next examined p21 protein expression in cell lysates after 48 h of 
morpholino incubation by western blotting analysis, which also revealed 
increased levels of p21 protein with either DANCR morpholino treatments (Figure 
26). These data demonstrate that DANCR is required for normal cell proliferation 















Figure 26. Levels of p21 protein increase after 48 h of vivo-morpholino 
treatment in P493 cells. Doses of 1.0 or 1.5 µM dosage for both morpholinos 













Does SnoRA26 confer effects on cell growth? 
By examining the genomic sequence of DANCR, I noticed a co-
transcribed small nucleolar RNA (SnoRNA), SnoRA26, in the second intron of 
DANCR (Figure 27A). To investigate the potential effects that SnoRA26 might 
have on the growth phenotypes that I observed in the loss of function studies of 
DANCR, I carried out the following experiments. 
First, I collected total RNA samples from DANCR siRNA-mediated 
transfection experiments at 24, 48, and 72 h post-transfection in PC3 cells and 
then performed qRT-PCR with pre-validated primer sets for DANCR and 
SnoRA26. Successful knock-down of DANCR was achieved; however, I 
observed no apparent change in SnoRA26 expression with the depletion of 
DANCR (Figure 27B), suggesting that the reduction in proliferation caused by 
reduced DANCR RNA levels was likely not associated with SnoRA26. 
Second, I designed a vivo-morpholino oligo to specifically target SnoRA26, 
followed by 72 h incubations with different concentrations of morpholinos in both 
PC3 and P493 cells. The efficacy of SnoRA26 blocking was assessed by qRT-
PCR for samples collected at 48 and 72 h time points post-treatment, Successful 
blocking was observed at both time points, especially at 48 h, with ~80% 
depletion of SnoRA26 RNA observed at almost all concentrations tested in both 
cell lines (Figure 28B and 29B). However, I observed no effects on the 
proliferation of PC3 cells and a lack of growth effects in P493 cells (Figures 28A 
and 29A). The only reduction in proliferation that I observed was in P493 cells 
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incubated with a higher dose of morpholino, which could be explained by the 
toxicity of the morpholinos. Note that 0.5 and 1 µM concentrations of morpholino-
treated P493 cells caused similarly high levels of SnoRA26 blockade (Figure 
29B), so the growth difference between the two conditions was unlikely to be a 
consequence of SnoRA26 blockade. 
Based on the experiments described above, I could rule out the 
involvement of SnoRA26 in any of the previously observed growth phenotypes, 




















       
 
 
Figure 27. SnoRA26 RNA not affected by DANCR depletion. (A) A diagram of 
DANCR transcript features. (B) A qRT-PCR analysis of RNA expression levels of 
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Figure 28. No effects of blocking SnoRa26 on the proliferation of PC3 cells. 
(A) The rates of cell proliferation were not changed after blocking of SnoRA226; 
three concentrations of morpholinos were used. (B) qRT-PCR analysis of 































































Figure 29. Lack of effects of blocking SnoRa26 on the proliferation of P493 
cells. (A) The rates of cellular proliferation were not changed after blockade of 
SnoRA226 with lower concentrations; four concentrations of morpholinos were 
used. (B) A qRT-PCR analysis of SnoRA26 RNA levels post-morpholino 





























































The MYC, DANCR, and p21 pathway 
Thus far, I have established that MYC targets DANCR directly in Chapter 
3 and that DANCR suppresses p21 earlier in this chapter. Considering these two 
findings together, I can propose a new pathway, MYC       DANCR       p21, 
adding to diverse modes of gene regulation by MYC. 
To validate my model, I re-analyzed the TCGA RNA-seq data, and found 
that the RNA expression levels of MYC and DANCR were significantly up-
regulated in specimens from patients with prostate cancer compared to normal 
prostate specimens. By contrast, p21 mRNA levels were significantly down-
regulated in these paired sample comparisons (Figure 30). These findings are 
consistent with this newly described pathway. Additionally, it is worth noting that 
the RNA abundance of DANCR was significantly higher than the mRNA 
abundance of p21 in specimens from patients with prostate cancer (Figure 31). 
This finding indirectly supports my hypothesis about the mechanism whereby 
DANCR can suppress p21, which is described in the next chapter. Notably, the 
expression levels of most lncRNAs were very low (~100-fold lower than that of 












Figure 30. DANCR, MYC, and p21 expression levels in prostate tumor 
versus normal samples. Data were obtained from TCGA prostate cancer RNA-
seq data analysis. Bar graphs indicate mean expression levels (n = 256 for 
tumors, n = 45 for normal samples; P < 0.0001 for DANCR, P < 0.0001 for Myc, 












Figure 31. The abundance of DANCR, MYC, and p21 RNA in prostate cancer. 
Data were obtained from TCGA prostate cancer RNA-seq analysis. Dot blots 
represent the expression level in each sample and the means of those values 





In the final part of this chapter, to further substantiate this proposed 
pathway, I performed a critical experiment in which I tested whether I could 
rescue the observed growth arrest in response to DANCR depletion in PC3 cells. 
A double knock-down of DANCR and p21 was performed in PC3 cells. As 
expected, the double knock-down partially rescued the reduction in proliferation 
caused by the DANCR knock-down alone (Figure 32). Although DANCR likely 
regulates the expression of many genes, I suspected that p21 is likely one of its 
most important targets, which is supported by the partial rescue of this phenotype. 
I also performed MYC and p21 knock-down in parallel; however, this failed to 
recapitulate a similar amount of rescue as DANCR/p21 double knock-down 
(Figure 33). This is possibly because among the many targets of MYC affected 




















   
 
 
Figure 32. Double knock-down of DANCR + p21 partially rescues the 
growth arrest induced by DANCR depletion in PC3 cells. (A) The rates of 
proliferation partially recovered by DANCR + p21 depletion; error bars indicate 
the standard deviation (n = 3). (B) Western blotting confirmed p21 induction by 
DANCR knock-down and depletion by the double knock-down. Tubulin was used 


































Figure 33. Double knock-down of MYC + p21 cannot rescue MYC depletion-
induced growth arrest in PC3 cells. (A) The rates of proliferation were not 
recovered by MYC + p21 depletion. (B) Measurements of MYC mRNA levels 
were confirmed by qRT-PCR for different time points. (C) The p21 mRNA levels 






































































Materials and methods 
Cell culture  
P493 and PC3 cells were grown as described in Chapter 2, and DU145 cells 
were a generous gift from Dr. Angelo De Marzo at Johns Hopkins Medical 
Institute. DU145 cells were cultured in RPMI 1640 with 10% Fetal Calf Serum 
(FCS), and 1% penicillin/streptomycin. 
 
RNA interference 
The siRNA duplexes directed against DANCR and a non-targeting controls were 
purchased from Ambion®. An on-target plus smart pool siRNA against MYC was 
purchased from Dharmacon Inc. All siRNAs were used according to 
manufacturer’s instructions. Briefly, cells were transfected using Lipofactamine 
2000 (Invitrogen), and 200,000 cells in 1ml serum-free media were transfected 
per well in six-well plates. A total of 3 μL Lipofectamine 2000 was used per well. 
The siRNAs were transfected at a final concentration of 50 nM. Then, 1 ml media 
containing 20% FBS was added 4–6 h following transfection. For larger cell 
numbers, reaction volumes were increased accordingly. Cells were counted, 





Cell proliferation assays 
Cells were stained with 0.4% trypan blue, and the number of viable cells was 
counted using a hemocytometer. 
 
Cell cycle analysis 
Cell cycle analysis was carried out using the FITC BrdU Flow Kit purchased from 
BD Pharmingen™ following manufacturer’s protocol. Cells were filtered and then 
analyzed by flow cytometry using a Becton Dickinson FACScan or FACS Calibur. 
Data analysis was carried out using FlowJo software. 
 
Microarray hybridization and analysis  
PC3 cells were transfected with DANCR, MYC, and NT control siRNAs and then 
were harvested after 72 h. The microarray experiment was carried out as 
described in Chapter 2. 
 
Western blotting 
For immunoblot analysis, cells were lysed in incomplete Laemmli buffer at 95°C. 
Concentrations of protein samples were determined using a bicinchoninic acid 
(BCA) kit (Pierce). Proteins were electrophoresed using precast Tris-HCl 
polyacrylamide gels (Bio-Rad) and transferred to nitrocellulose membranes with 
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a SNAP i.d.™ System (Millipore) for immunoblotting. Membranes were blocked 
and probed with primary and secondary antibodies. Signals were visualized 
either with ECL Western Blotting Detection Reagent (Amersham) and Hyperfilm 
ECL (Amersham) or, more recently, with an Odyssey Imaging System (LI-COR) 
and the accompanying v3.0 software. 
 
Morpholinos 
Vivo-morpholinos were designed and custom synthesized by GENE TOOLS, 
LLC. Cells were incubated with fixed concentrations of morpholinos for 48–72 h; 
notably, vivo-morpholinos do not require endo-porters for in vitro delivery. 
 
Quantitative real-time PCR (RNA quantitation and ChIP validation), survival 

























In previous chapters, I proposed the pathway MYC       DANCR      p21, 
and established that DANCR is directly induced by MYC. The major question that 
still remained was the exact mechanism whereby DANCR suppresses p21. 
Recently, several reports of functional characterizations of lncRNAs have been 
published. For example, HOTAIR can bind to histone modifying enzymes (PRC2 
and LSD1), thereby mediating target gene silencing through chromatin state 
modifications; and other reports showed that lncRNAs can promote cancer 
metastasis have emerged (Gupta et al., 2010; Khalil et al., 2009; Tsai et al., 
2010). These reports, combined with my finding that p21 is one of many 
overlapping genes that can be co-suppressed by DANCR and EZH2, prompted 
me to develop a model for DANCR and EZH2 targeting p21 (Figure 34). DANCR 
can bind to EZH2, and guides it to the p21 gene locus, where EZH2 induces 
H3K27me3 and changes the chromatin structure to a closed state, eventually 
shutting off p21 expression. 
In this chapter, I provide evidence for a DANCR–EZH2 partnership that 
can trigger a target gene silencing mechanism and propose a lncRNA gene 
targeting mode that occurs via RNA–RNA interactions. Several steps to confirm 







Further confirmation that p21 is an EZH2 target 
The first step to validate my model was to further confirm that EZH2 
directly regulates p21 in prostate cancer. Though there have been reports of 
EZH2 targeting p21 in some cell lines, I want to confirm this in prostate cancer 
cell lines too. I have previously shown that EZH2 binds to the p21 promoter by 
ChIP and validated this finding by qRT-PCR, showing over 5-fold enrichment of 
the EZH2 signal relative to IgG controls at p21 locus. Similar to previous 
experiments that showed DANCR suppression of p21, I performed one more 
experiment on EZH2–p21 using a loss-of-function approach using siRNA-
mediated double knock-down of EZH2 and p21 in PC3 and DU145 cells. After 
EZH2 depletion, p21 protein levels were significantly increased in both cell lines 
(Figure 35). This result further confirms that p21 is directly suppressed by EZH2. 
 
EZH2 directly binds to DANCR 
Next, I sought to establish the direct connection between EZH2 and 
DANCR through a series of binding experiments. RNA immunoprecipitation (RIP) 
of EZH2 from PC3 cells specifically recovered endogenous DANCR RNA. 
Conversely, IP for IgG did not retrieve DANCR, and neither EZH2 nor IgG IP 
retrieved U1 RNA, a nuclear ncRNA that served as a negative control (Figure 36). 
Thus, I confirmed that DANCR can be ‘pulled down’ by EZH2 IP. To be thorough 
and prove that this direct interaction is valid, I also performed a RNA pull-down 
assay. Biotin-labeled DANCR, antisense DANCR, and green fluorescent protein 
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(GFP) were in vitro transcribed and purified. RNAs were then mixed with PC3 
nuclear extracts and incubated at room temperature. Streptavidin-agarose beads 
were added, incubated with the mixture, washed, and boiled. The retrieved 
protein was detected by standard western blotting. Only purified biotinylated 
DANCR RNA, but not GFP RNA or an antisense DANCR RNA fragment, 
specifically retrieved EZH2 from PC3 cell nuclear extracts (Figure 37). 
To identify the specifi interaction domain required for  DANCR/EZH2 
interaction, I used a series of DANCR deletion mutants, and different lengths of 
DANCR fragments were in vitro transcribed (Figure 38). The EZH2-binding 
activity was mapped to the 3ʹ-end of DANCR transcripts, as only full-length 
DANCR was able to ‘pull-down’ EZH2, but not the fragments without the 3ʹ-end 




























Figure 34. A working model illustrating the potential mechanism of 


























Figure 35. Immunoblot of EZH2 and p21 protein levels after knock-down of 
either EZH2 alone or both EZH2 and p21. Protein samples from 48 and 72 h 
after transfection were measured by western blotting. Tubulin was used as a 



















Figure 36. EZH2 RIP specifically retrieves DANCR RNA. Bar graphs indicate 
retrieved RNA fold-changes compared to U1 snRNA. Data is normalized to 
mock-IP (immunoglobulin G). Error bars indicate standard deviation (n = 3). 












































Figure 37. In vitro transcribed (IVT) biotinylated DANCR retrieves EZH2 
protein. A total of 5% total input was included as a positive control, and both 
GFP and anti-sense DANCR were used as negative controls. EZH2 signals on 








































Figure 38. The 3ʹ-end of DANCR is required for EZH2 binding. Lanes 1–5 on 
the western blot correspond to the pull down blot from the fragments numbered 





















EZH2 binding to the p21 locus requires DANCR 
To determine whether DANCR is necessary for EZH2 binding to p21 and 
suppression of its expression, I designed a ChIP-qPCR experiment to test 
whether siRNA-mediated DANCR depletion would affect EZH2 binding to the p21 
locus. A locus nearby that has no previously reported EZH2 binding activity was 
selected as a negative control. Additionally, MYT1, a known EZH2 target for 
which expression did not seem to be affected by DANCR manipulation in my 
analysis, was also chosen as another negative control. I found that DANCR 
knock-down significantly reduced EZH2 binding at the p21 promoter region 
compared to the negative regions in both PC3 and DU145 cells, and MYT1 
binding by EZH2 did not appear to change after siRNA knock-down of DANCR 
(Figures 39 and 40). This finding suggests that DANCR is required for EZH2 














Figure 39. DANCR depletion reduces EZH2 binding at the p21 promoter 
locus in PC3 cells. Bar graphs represent the fold-change of the EZH2 ChIP 


































































Figure 40. DANCR depletion reduces EZH2 binding at the p21 promoter 
locus in DU145 cells. Bar graphs show the fold-change of EZH2 ChIP signals 
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DANCR targets p21 via RNA–RNA interactions 
The question of how DANCR targets p21 still remained, so I sought to 
address question of the exact mechanism whereby DANCR guides EZH2 to the 
p21 locus.  Since the early 1980’s, there have been reports identifying ncRNA 
interactions with pre-mRNAs through sequence complementary, which were 
followed by genetics and in vitro affinity binding experiments for validation 
(Lerner et al., 1980; Zhuang and Weiner, 1986). I suspected that DANCR might 
recognize p21 mRNA transcripts through complementary sequences via RNA–
RNA interactions. However, mapping of RNA–RNA interactions remains a 
challenge. Until recently, in silico approaches have been utilized to investigate 
RNA-RNA interactions (Dieterich and Stadler, 2013). I first attempted to predict 
DANCR–p21 mRNA interaction sites and to simulate the possible folding of the 
two using publically available software, IntaRNA (Busch et al., 2008; Wright et al., 
2014) and RNAfold webserver (http://rna.tbi.univie.ac.at/). A 5ʹ-domain of 
DANCR was computationally predicted to be most likely to interact with p21 
mRNA, consistent with my earlier finding that the 3ʹ-domain of DANCR is a 
binding site for EZH2 (Figure 41). 
The experimental design for validating that binding included first treating 
PC3 cells with Bortezomib to artificially increase the expression levels of p21 
mRNA, as the endogenous level of p21 in cancer cells was too low for detect any 
potential interactions (Figure 42B). A series of biotinylated DANCR fragments of 
different lengths, along with negative control antisense DANCR transcripts, were 
in vitro transcribed and incubated with total RNA purified from Bortezomib-treated 
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PC3 cells (Figure 42A). This mixture was cross-linked with 4ʹ-
aminomethyltrioxalen (AMT), a psoralen-derivative cross-linker that only 
generates cross-links between uridine bases in RNA, but does not react to 
proteins (Calvet and Pederson, 1979). Pull-down were then achieved by 
streptavidin agarose beads. mRNA levels for p21 and two negative controls 
(MYT1 and HOXC8, genes for which expression levels appeared not to be 
regulated by DANCR) were detected using qRT-PCR. The data shown in Figures 
43–46 confirmed my hypothesis that 5ʹ-end domain of DANCR interacts with p21 
mRNA.  
Together, these findings confirm my proposed mechanistic model for 


























Figure 41. Possible domain mediating DANCR–p21 mRNA interactions 
identified by IntaRNA and RNAfold. Simulated interaction was consistent with 
a minimum free energy model. The sequence and location of a possible binding 



















            
 
Figure 42. A schematic illustration of the experimental design for mapping 
DANCR–p21 mRNA interactions. (A) Experimental design: Blue bars represent 
in vitro transcribed DANCR fragments as baits, red square is the predicted p21 
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Figure 43. Full-length DANCR could specifically retrieve p21 mRNA. The 
fragment shown in blue was used to retrieve associated RNA molecules. NT is 
an antisense and was used as a negative control. MYT1 and HOX8 were also 
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Figure 44. A DANCR fragment containing the 5ʹ-end could specifically 
retrieve p21 mRNA. The fragment shown in blue was used to retrieve 
associated RNA molecules. NT indicates an antisense DANCR fragment used as 
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Figure 45. A DANCR fragment containing the 5ʹ-end could specifically 
retrieve p21 mRNA (continued). The fragment shown in blue was used to 
retrieve associated RNA molecules. NT is an antisense DANCR fragment that 
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Figure 46. A 3ʹ-end DANCR fragment cannot specifically retrieve p21 mRNA. 
The fragment shown in blue was used to retrieve associated RNA molecules. NT 
is an antisense DANCR fragment that was used as a negative control. MYT1 and 
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DANCR targets genes via RNA–RNA interactions as a general mechanism 
To this point, I validated the p21 gene silencing by DANCR–EZH2 
partnership model with experimental evidence. Whether this model can be 
applied to a larger group of genes targeted by this duo as a general mechanism 
remains an open question. In the final part of this thesis, I attempt to expand my 
proposed model using exploratory in silico methods. 
I selected 16 genes that included my validated DANCR target genes and 
the top DANCR target genes that were identified from the microarray analysis 
(Table 3). Similar to my approach for p21, the mRNA sequences of these 16 
transcripts were subjected to computational folding and binding simulations with 
DANCR by IntaRNA and RNAfold. I found that 8 of the mRNA transcripts for the 
16 genes have predicted DANCR-interacting domains that are exact matches or 
largely overlap with the DANCR–p21 RNA–RNA interaction domain at the 5ʹ-end 
of DANCR. More specifically, for CTSB, PDCD6, PIP4K2A, and SLC16A2, the 
putative binding sites are located on the 5ʹ-end of the respective pre-mRNA 
transcripts, and the sites on GAS6, GHR, KRT34, and LOXL4 are further away 
from the 5ʹ-ends, but remain within the first half of the pre-mRNA molecules 
(Figures 47 and 48). These findings suggest that the DANCR guiding EZH2 to 
targets via RNA–RNA recognition model proposed by us is not an isolated event 
that only applies to p21, but instead suggests that it could possibly account for 









































Figure 47. Predicted common interaction domains of DANCR and four of its 









































Figure 48. Predicted common interaction domains of DANCR and another 




Materials and Methods 
RNA immunoprecipitation  
The RIP experiment was carried out using a Magna RIP™ RNA-Binding Protein 
Immunoprecipitation Kit (Millipore) following the manufacturer’s protocol. 
 
RNA pull-down assay 
The RNA pull-down assay was carried out as previously described (Tsai et al., 
2010). Briefly, biotin-labeled RNAs were in vitro transcribed using Biotin-RNA 
Labeling Mix (Roche) and T7 RNA polymerase (Promega), treated with RNase-
free DNase I (Promega), and then purified with a RNeasy Mini Kit (QIAGEN). 
Biotinylated RNA was heated to 90°C for 2 min, incubated on ice for 2 min, 
supplied with RNA structure buffer, and then heated to room temperature for 20 
min to allow proper secondary structures to form. PC3 cell pellets were 
resuspended in PBS, nuclear isolation buffer, and incubated on ice for 20 min 
(with frequent mixing). Nuclei were pelleted by centrifugation at 2500×g for 15 
min. Nuclear pellets were resuspended in RIP buffer. Nuclear membranes and 
debris were pelleted by centrifugation at 13,000 RPM for 10 min. Folded RNA 
was then mixed with PC3 nuclear extracts in RIP buffer and incubated at room 
temperature for 1 h. Washed strepavidin-agarose beads (Invitrogen) were added 
to each binding reaction, which were further incubated at room temperature for 1 
h. Beads were washed and boiled in SDS buffer, and the retrieved protein was 




RNA–RNA interaction predictions 
The DANCR sequence was queried against target gene mRNA using intaRNA to 
predict the interaction domains between the two transcripts. Additionally, the 
RNA–RNA interaction MFE (minimum free energy) secondary structure was 
predicted using the RNAfold webserver. 
 
Cell culture, RNA interference, western blotting, quantitative real-time PCR, 
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